Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Oxford Science Enterprises

Neptune is a UK-based fund management company offering a range of ISA-friendly equity funds to private investors, advisers and institutional clients.

Neptune Investment Management

Future Planet Capital is the global impact-led venture capital firm built to back growth companies from the world's top universities and research ecosystems. The group manages $380m for institutional investors and has invested in over 300 companies, with 60 successful exits. It's portfolio is built around breakthrough technologies solving global challenges in Climate, Health, Education, Sustainable Growth and Climate Change.

Future Planet Capital

Fushia Investments

GT Healthcare Capital Partners (“GT Healthcare”) is an Asia-based private investment partnership that specializes in healthcare investments around the globe that aim to change technology landscapes.  GT Healthcare intends to provide capital and scale expertise to healthcare businesses in Asia / Greater China.

GT Healthcare Capital Partners

RT Ventures

Tanarra is an Australian family office investment and advisory firm.  Tanarra invests in a wide range of early-stage ventures, private and public companies in Australia and around the world. Current early-stage investments include Pexip, a world-leading video technology company based in Oslo; Genomics, an Oxford-based business using genetic analysis to improve pharma R&D investment returns; and Oxford PV, a new generation solar photovoltaic cell technology. Previous investments have included Business Spectator, the business media publication founded by well-known Australian journalist Alan Kohler, which was later acquired by News Corporation.

Tanarra Capital

We have a vision for the future in which data, computing, networks, and other digital and deep technologies deliver meaningful outcomes and insight for improving health and the provision of care. We believe the creation of new businesses is built on in-depth understanding of the complex network of healthcare system participants, and marrying that with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. We look for and seed founders determined to effectively and efficiently serve these participants on the european continent and internationally. We are committed to addressing needs across the care continuum, healthcare systems, and all specialties.

Nina Capital

The Blue Venture Fund is a strategic investment vehicle that aims to foster innovation within the healthcare system. The Blue Venture Fund invests in emerging healthcare companies that have the potential to improve the quality of care, enhance patient experience, and reduce costs. It seeks to support companies that align with the needs and priorities of Blue Cross Blue Shield (BCBS) member companies and their policyholders.

The Blue Venture Fund

Google Ventures invests in sectors including life sciences, consumer, enterprise, crypto, climate, and frontier technology. With Alphabet as its sole limited partner, Google Ventures focuses on long-term investments. Its operating partners assist startups in design, equity, diversity & inclusion, talent, and engineering and help them connect with Google for technology and expertise. Founded in 2009 as Google Ventures, Google Ventures manages over $8 billion in assets with 400 active portfolio companies in North America and Europe. Some notable investments include Uber, Nest, Slack, GitLab, and One Medical. Google Ventures is based in the San Francisco Bay Area with offices in Cambridge, New York, and London.

Google Ventures

Optum Ventures provides capital and strategic guidance to startup companies solving health care's pressing challenges. It is the venture capital investment arm of Optum that invests in digital health companies that use data and insights to help improve consumers' access to health care services and how care is delivered and paid for, and that makes the health care system more reliable and easier to navigate.

Optum Ventures

Ultromics

They are building world-class diagnostic aids to help cardiologists — powered by artificial intelligence. To date, they have developed the world’s most accurate echocardiography software to improve the diagnosis of coronary heart disease by more than 90%.

Ultromics is a patient outcomes-focused AI-driven health technology company specializing in precision heart failure detection. The company's flagship product, EchoGo, is an AI platform that transforms the way heart failure is diagnosed using artificial intelligence and cardiac ultrasound. The technology empowers clinicians to make precise, efficient, and accurate assessments of heart failure by leveraging the largest known heart disease outcomes dataset in echocardiography.

Ultromics Announces Partnership to Expedite Development of Echo AI Algorithm for Early Detection of Cardiac Amyloidosis

Ultromics gets FDA nod for AI-based heart failure detection device

New Technology Add-On Payment (NTAP) for Ultromics: Advancing HFpEF Diagnosis

Study Confirms Ultromics' AI Can Improve HFpEF Detection Using a Single Echocardiogram View

UK-based startup Ultromics secures £10 million investment for its AI heart diagnostics

Ultromics adds $33M to its AI-enabled cardiac imaging product portfolio

Ultromics’ heart failure AI: From a Breakthrough Device Designation to a billing code

Ultromics receives Breakthrough Device Designation for AI cardiac amyloidosis tool and more digital health briefs

Ultromics closes $33m Series B to fund AI-based cardiovascular diagnostic tools

Digital Health’s Game-changing Moment: Ultromics Receives FDA Designation for AI Cardiac Amyloidosis Tool

Ultromics granted FDA Breakthrough Device Status

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Ultromics granted Category III CPT reimbursement code for EchoGo® Heart Failure

Pfizer

Ultromics has partnered with Pfizer to expedite the development, validation, and FDA clearance of its EchoGo Amyloidosis algorithm.

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Mayo Clinic

To identify the markers of heart failure and alert doctors to potential heart failure by leveraging AI analysis of ultrasound heart scans.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Ultromics is a patient outcomes-focused AI-driven health technology company specializing in precision heart failure detection. The company's flagship product, EchoGo, is an AI platform that transforms the way heart failure is diagnosed using artificial intelligence and cardiac ultrasound. The technology empowers clinicians to make precise, efficient, and accurate assessments of heart failure by leveraging the largest known heart disease outcomes dataset in echocardiography.
The EchoGo platform encompasses several FDA-cleared AI algorithms, including EchoGo Core for detecting coronary artery disease (cleared in 2021), EchoGo Heart Failure for detecting heart failure with preserved ejection fraction (HFpEF) (cleared in November 2022), and EchoGo Amyloidosis for detecting cardiac amyloidosis (received Breakthrough Device Designation in April 2023). These algorithms analyze routine echocardiograms to detect various heart conditions that often go undiagnosed during standard assessments.
EchoGo Heart Failure, in particular, has demonstrated exceptional accuracy, with a sensitivity of 87.8% and specificity of 81.9% in identifying HFpEF patients, outperforming clinical algorithms. The technology received New Technology Add-On Payment (NTAP) from the Centers for Medicare & Medicaid Services in August 2023, facilitating its adoption and reimbursement for Medicare beneficiaries.
Ultromics has collaborated with renowned institutions like Mayo Clinic and NHS England to develop its technology. The company has raised over USD 50 million in capital from investors such as Blue Venture Fund, Optum Ventures, Oxford Science Enterprises, and GV to support continued innovation.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

Companies that use GenAI as a core part of their product offering for Clinical Decision Support Systems

Uses digital mediums to generate actionable insights from health data

Clinical Decision Support System providers incorporate GenAI to enhance their systems

In most cases, CDSSs are provided to healthcare providers

Uses IoT to connect databases with medical devices for decision support

Uses AI/ML to output decisions/recommended actions based on databases of medical records

Ultromics

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless